FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315621548> ?p ?o ?g. }

• W4315621548 endingPage "341" @default.
• W4315621548 startingPage "329" @default.
• W4315621548 abstract "More than 10% of HER2-positive metastatic breast cancer (mBC) will develop Central Nervous System (CNS) metastases as first and isolated site of relapse on trastuzumab and pertuzumab first-line therapy. However, few clinical data are available to guide the best strategy in this setting.Patients experiencing isolated CNS progression on trastuzumab and pertuzumab first-line therapy were retrospectively identified from the French Epidemiological Strategy and Medical Economics (ESME) real-life database between 2008 and 2016.Among 995 patients treated with first-line trastuzumab and pertuzumab for HER2-positive mBC, 132 patients (13%) experienced isolated CNS progression with a median time of 12 months after mBC diagnosis. Twelves patients did not receive any treatment and were excluded from the analysis. Among the 120 patients considered, 76 (63%) received CNS-directed local therapy, 73 (60%) continued trastuzumab and pertuzumab, whereas 47 (39%) started another systemic treatment. After a median follow-up of 21 months, there was no difference in progression-free survival for patient who continued trastuzumab-pertuzumab or switched to another systemic treatment. In multivariate analysis, trastuzumab-pertuzumab continuation was associated with longer OS (HR 0,28 IC 95%: 0,14-0,54 p < 0,001). mOS was not reached (95% 37.6-NE) and was 23.2 months (95% CI 15.5-53.6) in patients who continued trastuzumab and pertuzumab therapy and in patients who switched for another systemic therapy, respectively.In this real-life cohort, trastuzumab-pertuzumab continuation after local treatment for isolated CNS progression did not negatively impact PFS and OS. Prospective trials and assessment of new strategies are warranted in this specific situation." @default.
• W4315621548 created "2023-01-12" @default.
• W4315621548 creator A5005504247 @default.
• W4315621548 creator A5005973748 @default.
• W4315621548 creator A5011966180 @default.
• W4315621548 creator A5032686530 @default.
• W4315621548 creator A5035439475 @default.
• W4315621548 creator A5040961790 @default.
• W4315621548 creator A5041410352 @default.
• W4315621548 creator A5041911544 @default.
• W4315621548 creator A5043665560 @default.
• W4315621548 creator A5056565799 @default.
• W4315621548 creator A5058791215 @default.
• W4315621548 creator A5068016669 @default.
• W4315621548 creator A5069540694 @default.
• W4315621548 creator A5071553983 @default.
• W4315621548 creator A5074932302 @default.
• W4315621548 creator A5079006574 @default.
• W4315621548 creator A5079969896 @default.
• W4315621548 creator A5086379442 @default.
• W4315621548 creator A5090555713 @default.
• W4315621548 creator A5090562519 @default.
• W4315621548 creator A5090608495 @default.
• W4315621548 date "2023-01-11" @default.
• W4315621548 modified "2023-09-27" @default.
• W4315621548 title "Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort" @default.
• W4315621548 cites W1869027527 @default.
• W4315621548 cites W1986254095 @default.
• W4315621548 cites W2063083613 @default.
• W4315621548 cites W2063376924 @default.
• W4315621548 cites W2109176076 @default.
• W4315621548 cites W2125401809 @default.
• W4315621548 cites W2127199535 @default.
• W4315621548 cites W2130735457 @default.
• W4315621548 cites W2138692412 @default.
• W4315621548 cites W2162155075 @default.
• W4315621548 cites W2283853409 @default.
• W4315621548 cites W2460924712 @default.
• W4315621548 cites W2612893145 @default.
• W4315621548 cites W2624310346 @default.
• W4315621548 cites W2726463501 @default.
• W4315621548 cites W2734482945 @default.
• W4315621548 cites W2805948217 @default.
• W4315621548 cites W2806209829 @default.
• W4315621548 cites W2896524087 @default.
• W4315621548 cites W2897533777 @default.
• W4315621548 cites W2921590809 @default.
• W4315621548 cites W2979984433 @default.
• W4315621548 cites W2988134040 @default.
• W4315621548 cites W2994671294 @default.
• W4315621548 cites W2995808512 @default.
• W4315621548 cites W3012380787 @default.
• W4315621548 cites W3030461309 @default.
• W4315621548 cites W3039853672 @default.
• W4315621548 cites W3043096450 @default.
• W4315621548 cites W3109175864 @default.
• W4315621548 cites W3207557929 @default.
• W4315621548 cites W4200190043 @default.
• W4315621548 cites W4212864919 @default.
• W4315621548 doi "https://doi.org/10.1007/s12282-022-01427-0" @default.
• W4315621548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36630013" @default.
• W4315621548 hasPublicationYear "2023" @default.
• W4315621548 type Work @default.
• W4315621548 citedByCount "0" @default.
• W4315621548 crossrefType "journal-article" @default.
• W4315621548 hasAuthorship W4315621548A5005504247 @default.
• W4315621548 hasAuthorship W4315621548A5005973748 @default.
• W4315621548 hasAuthorship W4315621548A5011966180 @default.
• W4315621548 hasAuthorship W4315621548A5032686530 @default.
• W4315621548 hasAuthorship W4315621548A5035439475 @default.
• W4315621548 hasAuthorship W4315621548A5040961790 @default.
• W4315621548 hasAuthorship W4315621548A5041410352 @default.
• W4315621548 hasAuthorship W4315621548A5041911544 @default.
• W4315621548 hasAuthorship W4315621548A5043665560 @default.
• W4315621548 hasAuthorship W4315621548A5056565799 @default.
• W4315621548 hasAuthorship W4315621548A5058791215 @default.
• W4315621548 hasAuthorship W4315621548A5068016669 @default.
• W4315621548 hasAuthorship W4315621548A5069540694 @default.
• W4315621548 hasAuthorship W4315621548A5071553983 @default.
• W4315621548 hasAuthorship W4315621548A5074932302 @default.
• W4315621548 hasAuthorship W4315621548A5079006574 @default.
• W4315621548 hasAuthorship W4315621548A5079969896 @default.
• W4315621548 hasAuthorship W4315621548A5086379442 @default.
• W4315621548 hasAuthorship W4315621548A5090555713 @default.
• W4315621548 hasAuthorship W4315621548A5090562519 @default.
• W4315621548 hasAuthorship W4315621548A5090608495 @default.
• W4315621548 hasBestOaLocation W43156215483 @default.
• W4315621548 hasConcept C121608353 @default.
• W4315621548 hasConcept C126322002 @default.
• W4315621548 hasConcept C143998085 @default.
• W4315621548 hasConcept C201903717 @default.
• W4315621548 hasConcept C2775930923 @default.
• W4315621548 hasConcept C2779786085 @default.
• W4315621548 hasConcept C2781164504 @default.
• W4315621548 hasConcept C530470458 @default.
• W4315621548 hasConcept C71924100 @default.
• W4315621548 hasConcept C72563966 @default.
• W4315621548 hasConceptScore W4315621548C121608353 @default.

• next